Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elbasvir/Grazoprevir in HCV GT1b with Metabolic Syndrome
NCT03222167Phase 3Unknown
- Sponsor
- Institute of Cardiology and Internal Diseases
- Start
- Oct 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of elbasvir + grazoprevir in hepatitis C virus infection, sponsored by Institute of Cardiology and Internal Diseases. Status: unknown.
02
Drugs
elbasvir + grazoprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT03222167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03222167.